Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 126 Melanoma 92 Neoplasms 82 Colorectal Neoplasms 62 Squamous Cell Carcinoma of Head and Neck 61 Neoplasm Metastasis 59 Triple Negative Breast Neoplasms 51 Carcinoma, Renal Cell 47 Breast Neoplasms 39 Lung Neoplasms 37 Ovarian Neoplasms 32 Pancreatic Neoplasms 30 Head and Neck Neoplasms 29 Stomach Neoplasms 28 Urinary Bladder Neoplasms 26 Carcinoma, Transitional Cell 26 Endometrial Neoplasms 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Uterine Cervical Neoplasms 21 Carcinoma, Hepatocellular 18 Recurrence 15 Esophageal Neoplasms 15 Prostatic Neoplasms 14 Lymphoma 14 Small Cell Lung Carcinoma 12 Carcinoma, Squamous Cell 12 Kidney Neoplasms 11 Cholangiocarcinoma 11 Advanced Solid Tumor 11 Solid Tumor 10

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × rrCLL × pembrolizumab × Clear all

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡